CSL Behring gets U.S. FDA approval for hemophilia B therapy Idelvion

Pennsylvania-based CSL Behring, a unit of Australia's CSL, won a U.S FDA nod for Idelvion albutrepenonacog alfa (CSL654), a therapy to prevent or control bleeding in adults or children with hemophilia B. The approval follows a CHMP recommendation from the European Medicines Agency last week for marketing authorization of therapy of fusion protein linking recombinant coagulation Factor IX with recombinant albumin, the company said in a release. "Idelvion is the first and only factor IX therapy that delivers high-level protection with up to 14-day dosing in appropriate patients," the Melbourne-based parent company said. Release

Suggested Articles

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

A decree includes tax incentives for certain generic drugmakers and uniform insurance standards that apply to both branded drugs and generics.